5 May 2025 (36 Days) Date | | - Cons. EPS | - EPS |
3 Feb 2025 Date | | 4.02 Cons. EPS | 3.98 EPS |
4 Nov 2024 Date | | 4.14 Cons. EPS | 4.38 EPS |
1 Aug 2024 Date | | 2.94 Cons. EPS | - EPS |
30 Jul 2024 Date | | 4.17 Cons. EPS | - EPS |
5 May 2025 (36 Days) Date | | - Cons. EPS | - EPS |
3 Feb 2025 Date | | 4.02 Cons. EPS | 3.98 EPS |
4 Nov 2024 Date | | 4.14 Cons. EPS | 4.38 EPS |
1 Aug 2024 Date | | 2.94 Cons. EPS | - EPS |
30 Jul 2024 Date | | 4.17 Cons. EPS | - EPS |
Biotechnology Industry | Healthcare Sector | Dr. Jeffrey Marc Leiden M.D., Ph.D. CEO | NASDAQ (NGS) Exchange | US92532F1003 ISIN |
US Country | 5,400 Employees | - Last Dividend | - Last Split | 24 Jul 1991 IPO Date |
Vertex Pharmaceuticals Incorporated stands at the forefront of biotechnology innovation, focusing its efforts on the development and commercialization of therapies aimed at treating cystic fibrosis (CF), a debilitating genetic disorder. Since its establishment in 1989, the company has been pioneering in its approach to providing groundbreaking treatments that significantly improve the lives of those affected by CF. Operating from its headquarters in Boston, Massachusetts, Vertex extends its impact globally through the marketing of its advanced therapeutic solutions. Beyond cystic fibrosis, the company's research pipeline explores treatments for a variety of serious conditions including pain management, sickle cell disease, beta thalassemia, focal segmental glomerulosclerosis, Type 1 Diabetes, and cancer. Vertex's commitment to innovation is further underscored by its strategic collaborations with leading biotech entities such as CRISPR Therapeutics AG, Moderna, Inc., and several others, aiming to harness cutting-edge science in the development of novel therapies.